{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:12:23Z","timestamp":1791583943540,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA100632"],"award-info":[{"award-number":["CA100632"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA255721"],"award-info":[{"award-number":["R01 CA255721"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA262636"],"award-info":[{"award-number":["R01 CA262636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["AWD00006066"],"award-info":[{"award-number":["AWD00006066"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004388","name":"Teva Branded Pharmeceutical Products R&amp;D Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bneo.2025.100145","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T16:13:27Z","timestamp":1753460007000},"page":"100145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Omacetaxine and venetoclax in relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-3362","authenticated-orcid":false,"given":"Wei-Ying","family":"Jen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4533-5176","authenticated-orcid":false,"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravanthi","family":"Lavu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-1613","authenticated-orcid":false,"given":"Kelly","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-4895","authenticated-orcid":false,"given":"Musa","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1144-1958","authenticated-orcid":false,"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0957-6009","authenticated-orcid":false,"given":"Christopher P.","family":"Mill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7343-6214","authenticated-orcid":false,"given":"Warren","family":"Fiskus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil N.","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1-2","key":"10.1016\/j.bneo.2025.100145_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1615\/CritRevOncog.v16.i1-2.80","article-title":"RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making","volume":"16","author":"Mangan","year":"2011","journal-title":"Crit Rev Oncog"},{"issue":"11","key":"10.1016\/j.bneo.2025.100145_bib2","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/leu.2016.207","article-title":"RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features","volume":"30","author":"Gaidzik","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bneo.2025.100145_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081618","article-title":"Clinical outcomes and co-occurring mutations in patients with RUNX1-mutated acute myeloid leukemia","volume":"18","author":"Khan","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"26","key":"10.1016\/j.bneo.2025.100145_bib4","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1182\/blood-2009-05-223784","article-title":"AML1\/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations","volume":"114","author":"Tang","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100145_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.2018893982","article-title":"RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1","volume":"134","author":"Mill","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2025.100145_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/989434","article-title":"Rapamycin regulates iTreg function through CD39 and Runx1 pathways","volume":"2014","author":"Lu","year":"2014","journal-title":"J Immunol Res"},{"issue":"7","key":"10.1016\/j.bneo.2025.100145_bib7","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1158\/1078-0432.CCR-13-1283","article-title":"Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia","volume":"20","author":"Gandhi","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.bneo.2025.100145_bib8","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.2021013156","article-title":"Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2","volume":"139","author":"Mill","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2025.100145_bib9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bneo.2025.100145_bib10","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100145_bib11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/rssc.12089","article-title":"Bayesian optimal interval designs for phase I clinical trials","volume":"64","author":"Liu","year":"2015","journal-title":"J R Stat Soc C"},{"issue":"1","key":"10.1016\/j.bneo.2025.100145_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"16","key":"10.1016\/j.bneo.2025.100145_bib13","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"issue":"12","key":"10.1016\/j.bneo.2025.100145_bib14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100145_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"Journal of the Royal Statistical Society: Series B (Methodological)"},{"issue":"43","key":"10.1016\/j.bneo.2025.100145_bib16","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.bneo.2025.100145_bib17","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.bneo.2025.100145_bib18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","article-title":"Venetoclax combined with azacitidine and homoharringtonine in relapsed\/refractory AML: a multicenter, phase 2 trial","volume":"16","author":"Jin","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100145_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/1078-0432.CCR-24-1332","article-title":"Homoharringtonine added to venetoclax and azacitidine improves outcome and mitigates genetic impact in relapsed\/refractory AML: a multicenter cohort study","volume":"31","author":"Yu","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"31","key":"10.1016\/j.bneo.2025.100145_bib20","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1200\/JCO.22.02836","article-title":"Homoharringtonine-based induction regimen improved the remission rate and survival rate in Chinese childhood AML: a report from the CCLG-AML 2015 protocol study","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100145_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clml.2014.09.011","article-title":"Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies","volume":"15","author":"Kantarjian","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.bneo.2025.100145_bib22","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.1016\/j.clml.2021.06.002","article-title":"Efficacy and safety of homoharringtonine for the treatment of acute myeloid leukemia: a meta-analysis","volume":"21","author":"Mi","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.bneo.2025.100145_bib23","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00432-024-05861-9","article-title":"Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia","volume":"150","author":"Yin","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100145_bib24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/1097-0142(19890301)63:5<813::AID-CNCR2820630502>3.0.CO;2-V","article-title":"Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia","volume":"63","author":"Kantarjian","year":"1989","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bneo.2025.100145_bib25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1200\/JCO.1985.3.5.617","article-title":"Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia","volume":"3","author":"Warrell","year":"1985","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100145_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-012-1963-2","article-title":"Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors","volume":"71","author":"Nemunaitis","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100145_bib27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1634\/theoncologist.2013-0077","article-title":"U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia","volume":"19","author":"Alvandi","year":"2014","journal-title":"Oncologist"},{"issue":"13","key":"10.1016\/j.bneo.2025.100145_bib28","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100145_bib29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ajh.25318","article-title":"A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents","volume":"94","author":"Short","year":"2019","journal-title":"Am J Hematol"},{"issue":"suppl 15","key":"10.1016\/j.bneo.2025.100145_bib30","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1200\/jco.2013.31.15_suppl.7068","article-title":"Results of omacetaxine plus low-dose cytarabine (LD-araC) in older patients with acute myeloid leukemia (AML)","volume":"31","author":"Kadia","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100145_bib31","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cncr.32534","article-title":"Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:41:26Z","timestamp":1772923286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2950328025000809"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100145","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omacetaxine and venetoclax in relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100145"}}